In recent years, India has cemented its position as a vital player in the global pharmaceutical landscape. This growth is largely driven by its Contract Research Development and Manufacturing Organization (CRDMO) sector, which is poised for significant expansion. A recent report by Macquarie Equity Research highlights key factors contributing to India’s growing attractiveness as a destination for global pharmaceutical companies.
Market Growth Potential
The Indian CRDMO market, currently valued at approximately USD 7 billion, is projected to double by 2028, reaching around USD 14 billion. This remarkable growth is expected to continue at a compound annual growth rate (CAGR) of around 14%. Additionally, with regulatory developments such as the US Biosecure Act, India’s CRDMO industry could see enhanced growth, potentially reaching an estimated USD 22 billion by 2030.
Key Drivers of Growth
1. Pharmaceutical Outsourcing: A significant trend has emerged in which global pharmaceutical companies increasingly outsource research and manufacturing tasks to third-party organizations. This outsourcing trend stems from the need for cost-effective, efficient production capabilities.
2. Regulatory Support: An evolving regulatory landscape is advantageous to Indian companies. Policies supporting pharmaceutical manufacturing have significantly improved the compliance framework, allowing Indian firms to procure necessary approvals from prestigious bodies like the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
3. Geopolitical Factors: Ongoing geopolitical tensions have prompted pharmaceutical companies to diversify their supply chains. This shift diminishes reliance on traditional manufacturing hubs, especially China, thus creating fresh opportunities for the Indian market.
4. Cost Advantages: Indian CRDMOs offer competitive pricing, with manufacturing costs estimated to be 30-40% lower than those in Western countries. This price advantage is crucial in attracting foreign investments and collaborations in drug development.
Areas of Expertise
India is particularly recognized for its strengths in specific domains within pharmaceuticals:
– Active Pharmaceutical Ingredients (APIs): The country is one of the leading producers of APIs, supplying numerous global markets.
– Highly Potent APIs (HPAPIs): As demand rises for specialized and potent drugs, India’s expertise in HPAPIs sets it apart.
– Specialty Chemicals: The ability to manufacture specialized chemicals adds another dimension to India’s comprehensive pharmaceutical offerings.
-NSH Digidesk
